C4 Therapeutics (NASDAQ:CCCC) Upgraded to Hold at Wall Street Zen

C4 Therapeutics (NASDAQ:CCCC) was upgraded by Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also recently commented on CCCC. TD Cowen restated a “buy” rating on shares of C4 Therapeutics in a research report on Thursday. Barclays lifted their price target on shares of C4 Therapeutics from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a report on Wednesday, January 21st. Finally, Brookline Capital Acquisition boosted their price target on C4 Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, C4 Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $12.20.

C4 Therapeutics Trading Down 2.9%

NASDAQ:CCCC opened at $2.70 on Friday. C4 Therapeutics has a 12 month low of $1.09 and a 12 month high of $3.65. The company has a 50-day moving average price of $2.09 and a 200-day moving average price of $2.36. The stock has a market cap of $261.67 million, a price-to-earnings ratio of -1.99 and a beta of 2.96.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.25. C4 Therapeutics had a negative net margin of 292.08% and a negative return on equity of 60.16%. The business had revenue of $11.02 million during the quarter, compared to analyst estimates of $4.48 million. Equities analysts forecast that C4 Therapeutics will post -1.52 EPS for the current fiscal year.

Hedge Funds Weigh In On C4 Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Zacks Investment Management purchased a new stake in C4 Therapeutics in the third quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd bought a new position in shares of C4 Therapeutics during the 3rd quarter valued at $43,000. Delta Investment Management LLC purchased a new position in shares of C4 Therapeutics in the 4th quarter worth $38,000. Virtu Financial LLC purchased a new stake in C4 Therapeutics during the fourth quarter valued at $39,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in C4 Therapeutics in the second quarter worth about $31,000. Institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.